The ROC curve indicatedthat the diagnostic value was markedly improved by combing four biomarkers(CD66b/CD63+ NEVs, miR-223-2p, CEA, and CA199, termed ascFB), with an AUC of 0.894 to differentiate GC patients from HC, 0.823for GC in I/II stages, and 0.907 for GC in III/IV stages (Figure 5I). This evidence concerns the gene CEACAM5 and gastric cancer.